Atlas One · Host Biology · Scale 07 — System

Binge Eating Disorder

Binge Eating Disorder (2-3% prevalence; most common US eating disorder) characterized by recurrent loss-of-control eating without compensation; driven by dopamine reward dysregulation, serotonin hypofunction, and ghrelin dysregulation. Lisdexamfetamine (Vyvanse) is FDA-approved.

Also known as: binge eating disorder, BED, compulsive overeating, loss of control eating, binge eating, food addiction

Scale 07 — SystemScale
draftStatus
2026-06-08Last Reviewed
This is an auto-generated stub page built from atlas entry frontmatter. A richer hand-crafted page is planned. See the atlas source for the full entry including detailed body sections.
binge-eating-disorder

Binge Eating Disorder

Binge Eating Disorder (2-3% prevalence; most common US eating disorder) characterized by recurrent loss-of-control eating without compensation; driven by dopamine reward dysregulation, serotonin hypofunction, and ghrelin dysregulation. Lisdexamfetamine (Vyvanse) is FDA-approved.

Entry Metadata

FieldValue
IDbinge-eating-disorder
NameBinge Eating Disorder
Statusdraft
Last reviewed2026-06-08
Atlas01-human
Scale07-system

Cross-Atlas Connections

connects-toDopamine connects-toSerotonin connects-toGhrelin connects-toBdnf targetsBrain connects-toEndocannabinoid

Sources